Lilly Launches Tanstrive (Selpercatinib), a RET Inhibitor to Treat Advanced Cancers with RET Gene Alteration
3 Articles
3 Articles
A new and modern medicine has become available for the treatment of cancer in India. Well-known American pharma company Eli Lilly has launched an anti-cancer drug called Tanstrive in the Indian market. The company claims that this medicine can be especially effective for patients whose body has a change in a gene called RET. Usually, chemotherapy is used in the treatment of cancer, which affects many cells of the body. But Tanstrive is a targete…
Lilly launches Tanstrive (Selpercatinib), a RET inhibitor to treat advanced cancers with RET gene alteration
Eli Lilly and Company India announced the launch of Tanstrive (selpercatinib) in India, following marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene. Tanstrive (selpercatinib) is designed to selectively target RET alterations and block the abnormal signalling pathways that drive tumour growth. As an ora…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
